NCT04284202

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: The Affiliated Hospital of Qingdao University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evalute the efficacy and safety of PD-1 antibody combined with Dasatinib as third-line therapy for NSCLC patients with ARID1A mutation until disease progression or intolerable toxicity or patients withdrawal of consent. The target sample size is 30+individuals. The primary endpoint of this study is PFS、ORR、OS and the secondary endpoint is toxicity.

Conditions

• NSCLC Stage IV
• ARID1A
• PD-1

Interventions

Type	Name	Description
DRUG	PD-1 plus Dasatinib	Toripalimub 240mg injection day1; Dasatinib 100mg po qd day1-day21. 3weeks is 1 cycle.

Timeline

• Start date: 2020-03-01
• Primary completion: 2020-12-31
• Completion: 2021-12-31
• First posted: 2020-02-25
• Last updated: 2020-02-25

Locations

1 site across 1 country: China